The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Cbeyond's revenues will compress -3.6% and EPS will remain in the red.
The average estimate for revenue is $118.9 million. On the bottom line, the average EPS estimate is -$0.08.
Last quarter, Cbeyond chalked up revenue of $121.5 million. GAAP reported sales were 0.8% lower than the prior-year quarter's $122.5 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, EPS came in at $0.06. GAAP EPS were $0.06 for Q3 compared to -$0.04 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 68.2%, 120 basis points better than the prior-year quarter. Operating margin was 3.3%, 400 basis points better than the prior-year quarter. Net margin was 1.6%, 250 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $488.0 million. The average EPS estimate is $0.04.
The stock has a one-star rating (out of five) at Motley Fool CAPS, with 106 members out of 141 rating the stock outperform, and 35 members rating it underperform. Among 43 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 28 give Cbeyond a green thumbs-up, and 15 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Cbeyond is hold, with an average price target of $9.17.
Looking for alternatives to Cbeyond? It takes more than great companies to build a fortune for the future. Learn the basic financial habits of millionaires next door and get focused stock ideas in our free report, "3 Stocks That Will Help You Retire Rich." Click here for instant access to this free report.
- Add Cbeyond to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Why Sarepta Therapeutics, Cbeyond, and Advanced Micro Devices Are Today's 3 Best Stocks
The S&P 500 makes it a perfect five-for-five as Sarepta Therapeutics, Cbeyond, and Advanced Micro Devices all skyrocket higher.
Why Cbeyond Inc. Shares Skyrocketed
Is this meaningful or just another movement?
Cbeyond Beats on EPS But GAAP Results Lag
Just the facts, Fool.